arGEN-X Raises €9.5 Million
arGEN-X, a Dutch drug company focused on antidoby discovery and development, has raised €9.5 million in Series A funding. Forbion Capital Partners and LSP co-led the round, and were joined by KBC Private Equity, BioGeneration Ventures and seed backers Erasmus MC Biomedical Fund and Thuja Capital Healthcare Funds.
10 September 2009•6 mins read
